Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Tracy Nguyen
- Phone Number: 877-232-7974
- Email: info@adarx.com
Study Locations
-
-
-
Sydney, Australia, NSW 2139
- Recruiting
- ADARx Clinical Site
-
Woolloongabba, Australia, QLD 4102
- Recruiting
- ADARx Clinical Site
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Recruiting
- ADARx Clinical Site
-
Wollongong, New South Wales, Australia, 2500
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Hong Kong, Hong Kong, 2500
- Recruiting
- ADARx Clinical Site
-
Shatin, Hong Kong
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Bergamo, Italy, 24020
- Recruiting
- ADARx Clinical Site
-
Bologna, Italy, 40138
- Recruiting
- ADARx Clinical Site
-
Pavia, Italy, 27100
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Cheonan, South Korea, 31151
- Recruiting
- ADARx Clinical Site
-
Daegu, South Korea, 42601
- Recruiting
- ADARx Clinical Site
-
Gyeonggi-do, South Korea, 05278
- Recruiting
- ADARx Clinical Site
-
Seoul, South Korea, 03722
- Recruiting
- ADARx Clinical Site
-
Seoul, South Korea, 02841
- Recruiting
- ADARx Clinical Site
-
Seoul, South Korea, 03080
- Recruiting
- ADARx Clinical Site
-
Seoul, South Korea, 05278
- Recruiting
- ADARx Clinical Site
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, South Korea, 26426
- Recruiting
- ADARx Clinical Site
-
-
Gurogu
-
Gyeonggi-do, Gurogu, South Korea, 16499
- Recruiting
- ADARx Clinical Site
-
Seoul, Gurogu, South Korea, 08308
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- ADARx Clinical Site
-
Madrid, Spain, 28041
- Recruiting
- ADARx Clinical Site
-
Madrid, Spain, 28040
- Recruiting
- ADARx Clinical Site
-
Seville, Spain, 41009
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833401
- Not yet recruiting
- ADARx Clinical Site
-
New Taipei City, Taiwan, 110
- Recruiting
- ADARx Clinical Site
-
-
-
-
-
Newcastle upon Tyne, United Kingdom, UK, NE7 7DN
- Recruiting
- ADARx Clinical Site
-
-
BC
-
Leicester, BC, United Kingdom, LE5 4PW
- Recruiting
- ADARx Clinical Site
-
-
-
-
Florida
-
Doral, Florida, United States, 33122
- Withdrawn
- ADARx Clinical Site
-
Miami, Florida, United States, 33127
- Recruiting
- ADARx Clinical Site
-
Pembroke Pines, Florida, United States, 33029
- Withdrawn
- ADARx Clinical Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- ADARx Clinical Site
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Withdrawn
- ADARx Clinical Site
-
-
Michigan
-
Shelby, Michigan, United States, 48315
- Recruiting
- ADARx Clinical Site
-
-
New York
-
Great Neck, New York, United States, 11021
- Recruiting
- ADARx Clinical Site
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- ADARx Clinical Site
-
-
South Dakota
-
Dakota Dunes, South Dakota, United States, 57049
- Recruiting
- ADARx Clinical Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Withdrawn
- ADARx Clinical Site
-
Houston, Texas, United States, 77027
- Recruiting
- ADARx Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mean eGFR greater than or equal to 30 mL/min/1.73m2
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Exclusion Criteria:
- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections
- Received complement inhibitor treatments
- Active systemic viral, bacterial, or fungal infection
- Abnormal liver function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ADX-038 Dose Level 1 - IgAN
|
siRNA duplex oligonucleotide |
|
Experimental: ADX-038 Dose Level 2 - IgAN
|
siRNA duplex oligonucleotide |
|
Experimental: ADX-038 Dose Level 1 - C3G or IC-MPGN
|
siRNA duplex oligonucleotide |
|
Experimental: ADX-038 Dose Level 2 - IgAN, C3G, or IC-MPGN
|
siRNA duplex oligonucleotide |
|
Experimental: ADX-038 Dose Level 3 - IgAN, C3G, or IC-MPGN
|
siRNA duplex oligonucleotide |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the safety and tolerability of ADX-038
Time Frame: Length of study - From Day 1 through Month 24
|
Incidence and severity of TEAEs |
Length of study - From Day 1 through Month 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
24-hour Urine
Time Frame: Month 12
|
Change from baseline to Month 12 in urine protein-creatinine ratio, measured using 24-hour urine |
Month 12
|
|
Spot Urine
Time Frame: Month 12
|
Change from baseline to Month 12 in urine protein-creatinine ratio, measured using spot urine. |
Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Arezoo Mirad, MD, ADARx Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ADX-038-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.